ACC.26前瞻：會議日程搶先一覽，中國學者成果將再次亮相

ACC.26

北京時間3月28日至31日，由美國心臟病學會（ACC）舉辦的心血管領域盛會——ACC.26學術會議將在美國新奧爾良隆重舉行。作為全球頂尖心血管學術盛會，ACC年會將匯聚來自全球的20，000余名專業人士，通過互動式研討、學術交流及產品博覽會等形式，推動心血管領域的創新發展。

本次會議特別值得關注的是，多位中國心血管研究專家將報告其團隊的重要研究成果，展現中國學者在國際頂尖學術舞臺上的影響力。其中，中國人民解放軍東部戰區總醫院唐春香教授與郭翔教授、中國醫學科學院阜外醫院康連鳴教授將分別報告其團隊在冠狀動脈疾病無創評估、人群篩查及心肌病治療領域的前沿成果。

具體日程讓我們一起先睹為快！

01

重要指南更新值得關注

除了前沿臨床研究，本次會議將發布：

·2026年血脂異常管理指南

·2026年急性肺栓塞指南

這些指南將為臨床實踐提供重要參考，促進心血管疾病診療的標準化和規范化。

02

最新突破性臨床試驗（LBCT）

LBCT I

北京時間：3月28日 23:30-00:30

Ultrasound-Facilitated Catheter-Directed Thrombolysis Vs Anticoagulation Alone For Acute Intermediate-High-Risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial

急性中高危肺栓塞超聲輔助導管導向溶栓對比單純抗凝治療：HI-PEITHO隨機臨床試驗主要結果

匯報人：Stavros V. Konstantinides

Outcomes in Patients With Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial

比較隨機接受左心耳封堵術或口服抗凝治療的房顫患者的結局：CHAMPION-AF臨床試驗的主要結果

匯報人：Saibal Kar

Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results From the STEMI-Door to Unload Randomized Clinical Trial

無心源性休克前壁ST段抬高型心肌梗死的早期左心室減負荷治療：STEMI-Door to Unload隨機臨床試驗結果

匯報人：Navin Kapur

LBCT II

北京時間：3月29日 5:45-6:45

Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled HypertensionKARDINAL

研究：評估Tonlamarsen治療未控制高血壓的2期臨床試驗

匯報人：Luke Laffin

Evolocumab in Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

依洛尤單抗在無顯著動脈粥樣硬化患者中的應用：VESALIUS-CV研究結果

匯報人：Nicholas Marston

Intensive Low-Density Lipoprotein Cholesterol Targeting in Patients With Atherosclerotic Cardiovascular Disease

動脈粥樣硬化性心血管疾病患者強化低密度脂蛋白膽固醇目標值探索

匯報人：Yong-Joon Lee

DASH-Patterned Groceries to Reduce Blood Pressure Among Adults With Treated Hypertension: Results From the GoFreshRx Randomized Clinical Trial

為經治療的高血壓成人提供DASH模式食品以降低血壓：GoFreshRx隨機臨床試驗結果

匯報人：Stephen Paul Juraschek

LBCT III

北京時間：3月29日 22:30-23:30

Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading (CHIP-BCIS3)

高危冠狀動脈介入治療中經皮左心室減負荷技術的對照試驗：CHIP-BCIS3研究

匯報人：Divaka Perera

A Large-Scale, Global Randomized Trial of Coronary Physiology Derived From Conventional Angiography Compared With An Invasive Pressure Wire-Based Approach to Guide Percutaneous Coronary Intervention

一項大規模全球隨機試驗：比較基于常規造影衍生的冠狀動脈生理學與基于有創壓力導絲的方法指導經皮冠狀動脈介入治療

匯報人：Ajay J. Kirtane

A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina- ORBITA-CTO Trial

穩定型心絞痛患者慢性完全閉塞病變經皮冠狀動脈介入治療的隨機、安慰劑對照試驗——ORBITA-CTO試驗

匯報人：Sarosh A. Khan

Fractional Flow Reserve or 3d-quantitative Coronary Angiography-Based Vessel-Ffr Guided Revascularization – The Fast Iii Trial

血流儲備分數或基于3D定量冠狀動脈造影的血管FFR指導血運重建——Fast III試驗

匯報人：Joost Daemen

LBCT IV

北京時間：3月30日 00:45-1:45

Spironolactone in the Treatment of Heart Failure

螺內酯治療心力衰竭

匯報人：Frank Edelmann

Efficacy and Safety of Sotatercept in Combined Post- and Pre-Capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Results From the Phase 2 Cadence TrialSotatercept

在射血分數保留型心力衰竭相關的毛細血管前后混合性肺動脈高壓中的療效與安全性：2期Cadence試驗結果

匯報人：Mardi Gomberg-Maitland

Lung Impedance-Guided Therapy in Heart Failure With Preserved Ejection Fraction: Results of a Randomized Clinical Trial

基于肺阻抗監測指導射血分數保留型心力衰竭治療：一項隨機臨床試驗結果

匯報人：Michael Kleiner Shochat

Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM TrialMavacamten

用于有癥狀的青少年梗阻性肥厚型心肌病患者：來自3期Scout-HCM試驗的結果

匯報人：Joseph William Rossano

LBCT V

北京時間：3月30日 6:00-7:00

Redo-Surgery Versus Transcatheter Valve-In-Valve For Mitral Bioprosthetic Dysfunction: The SURVIV Trial

再次外科手術 vs. 經導管瓣中瓣技術治療二尖瓣生物瓣功能障礙：SURVIV試驗

匯報人：Dimytri Siqueira

Transcatheter Aortic Valve Implantation Without Routine Percutaneous Coronary Intervention: A Randomized Controlled Trial

不常規進行經皮冠狀動脈介入治療的經導管主動脈瓣植入術：一項隨機對照試驗

匯報人：Michiel Voskuil

Protect The Head To Head Trial: Randomized Comparison of Emboliner Embolic Protection Catheter Vs. Sentinel Cerebral Protection System During Transcatheter Aortic Valve ReplacementProtect The Head to Head

試驗：Emboliner栓塞保護導管與Sentinel腦保護系統在經導管主動脈瓣置換術中的隨機對比研究

匯報人：Adam B. Greenbaum

Two-Year Outcomes After Transcatheter Tricuspid Repair Without Cross-over in the Randomized Tri-fr TrialTri-Fr

隨機試驗中無交叉治療的經導管三尖瓣修復術后兩年結局

匯報人：Erwan Donal

LBCT VI

北京時間：3月30日 22:30-23:30

Heartline Study: A Decentralized Randomized Trial of Apple Watch and iPhone-Facilitated AF Detection and Cardiovascular Outcomes in Older Adults Without Known Atrial FibrillationHeartline

研究：一項基于蘋果手表與iPhone的無癥狀老年人房顫篩查及心血管結局分散式隨機試驗

匯報人：C. Michael Gibson

Digoxin in Rheumatic Heart Disease: A Multi-Center, Randomized, Double Blind, Placebo-controlled Trial

地高辛用于風濕性心臟病：一項多中心、隨機、雙盲、安慰劑對照試驗

匯報人：Ganesan Karthikeyan

Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction

急性心肌梗死后病情穩定患者停用β受體阻滯劑治療

匯報人：Joo-Yong Hahn

Effect of Intensive Triglyceride Lowering With Olezarsen on Progression of Coronary Atherosclerosis: A Coronary Cta Substudy of The Essence-TIMI 73b Randomized TrialOlezarsen

強化降低甘油三酯對冠狀動脈粥樣硬化進展的影響：Essence-TIMI 73b隨機試驗的冠狀動脈CTA亞組研究

匯報人：Nicholas Marston

LBCT VII

北京時間：3月31日 00:45-1:45

Primary Efficacy and Safety Results From the Phase 3 Sirolimus-Coated Balloon For Infra-inguinal Peripheral Arterial Disease (SirPAD) Trial

西羅莫司涂層球囊治療腹股溝下外周動脈疾病的3期SirPAD試驗主要療效與安全性結果

匯報人：Stefano Barco

Intravascular Ultrasound Guidance For Complex High-Risk Indicated Procedures – The Ivus Chip Trial

血管內超聲指導復雜高危有指征手術——Ivus Chip試驗

匯報人：Roberto Diletti

03

特色臨床研究（FCR）

FCR I

北京時間：3月29日 02:00-03:00

A Prospective Multicenter Registry to Define Coronary Vasomotor Disorders in Ischemia With Nonobstructive Coronary Arteries: Primary Results of Discover Inoca

一項前瞻性多中心注冊研究旨在明確非阻塞性冠狀動脈缺血中的冠狀動脈血管舒縮功能障礙：DISCOVER INOCA研究主要結果

匯報人：Samit M. Shah

Impact of Ivabradine on Orthostatic Intolerance, Quality of Life and Heart Rate in Post-Covid Postural Orthostatic Tachycardia Syndrome: Results From the Recover-Autonomic Trial

伊伐布雷定對新冠后體位性心動過速綜合征患者直立不耐受、生活質量及心率的影響：RECOVER-AUTONOMIC試驗結果

匯報人：Saibal Kar

Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Sex Differences in Underlying Causes of Myocardial Infarction With No Obstructive Coronary Arteries

應用冠脈光學相干斷層掃描與心臟磁共振成像探究非阻塞性冠脈心肌梗死病因的性別差異

匯報人：Harmony R. Reynolds

A Sham Controlled Randomised Trial Evaluating the Safety, Acceptability and Efficacy of Autonomic Neuromodulation Using Trans-Cutaneous Vagal Sensory Stimulation in Uncontrolled Hypertensive Patients

評估經皮迷走神經感覺刺激用于未控制高血壓患者自主神經調節的安全性、可接受性與有效性：一項假刺激對照隨機試驗

匯報人：Ajay K. Gupta

FCR II

北京時間：3月29日 03:30-04:30

Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes

替西帕肽對比度拉糖肽對擴展心腎結局的影響

匯報人：Steven E. Nissen

Prevalence and Clinical Impact of Hypercortisolism in Individuals With Resistant Hypertension: Primary Results From the Momentum Study難治性高血壓患者中皮質醇增多癥的患病率與臨床影響：MOMENTUM研究的主要結果

匯報人：Deepak L. Bhatt

Reliability of CAC=0 to Exclude Coronary Plaque in Diverse Global Cohorts: A Global Probability Study of Coronary Artery Disease (GPS-CAD) Analysis

CAC=0在不同種族隊列中排除冠脈斑塊的可靠性評估：全球冠狀動脈疾病概率研究（GPS-CAD）數據分析

匯報人：Lohendran Baskaran

Community-to-Clinic Linkage Implementation Program to Prevent Hypertension in Barbershops

基于理發店的社區-診所聯動高血壓預防計劃實施研究

匯報人：Joseph E. Ravenell

FCR III

北京時間：3月30日 02:15-03:15

10-year Follow-up of Clopidogrel Vs Aspirin Monotherapy in Stable Coronary Artery Disease After Percutaneous Coronary Intervention With Drug-eluting Stent

藥物洗脫支架經皮冠狀動脈介入治療后，氯吡格雷對比阿司匹林單藥治療穩定型冠狀動脈疾病的10年隨訪

匯報人：Hyo-Soo Kim

Coronary CT Derived Fractional Flow Reserve-guided Management of Patients With Stable CAD: 3-year Outcomes From A Multicentre, Pragmatic, Open-label, Randomised Controlled Trial in China

冠狀動脈CT衍生的血流儲備分數指導的穩定型冠狀動脈疾病患者管理：一項中國多中心、實用性、開放標簽、隨機對照試驗的3年結果

匯報人：唐春香 中國人民解放軍東部戰區總醫院

Role of Screening With Coronary Computed Tomography Angiography in Lipid Management in an Asymptomatic Chinese Population: A Community-Based, Parallel-Group, Open-Label, Randomized Clinical Trial (RESPECT2)

冠狀動脈CT血管造影篩查在無癥狀中國人群血脂管理中的作用：一項基于社區的、平行組、開放標簽、隨機臨床試驗（RESPECT2）

匯報人：郭翔中國人民解放軍東部戰區總醫院

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure對高風險糖尿病患者進行針對性評估以識別未確診的心力衰竭

匯報人：Daniel Taylor-Sweet

FCR IV

北京時間：3月30日 03:45-04:45

Automated Notifications to Improve Referral and Treatment of Severe Aortic Stenosis and Mitral Regurgitation: Outcomes From the Randomized Alert Trial

自動化通知改善重度主動脈瓣狹窄和二尖瓣反流的轉診與治療：隨機ALERT試驗的結果

匯報人：Wayne B. Batchelor

A Randomized Controlled Trial of a Novel Just-in-Time Adaptive Mobile Application Intervention to Reduce Sodium Intake and Blood Pressure in Patients With Hypertension

一項關于新型即時適應性移動應用程序干預以降低高血壓患者鈉攝入和血壓的隨機對照試驗

匯報人：Michael Dorsch

NOTIFY-HF: A Randomised Pilot Trial of Patient-Facing Heartlogic Alerts in Heart Failure Patients

NOTIFY-HF：一項面向心力衰竭患者的HeartLogic警報的隨機試點試驗

匯報人：Joseph Assad

MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure): A Randomized Controlled Trial of an Indigenous Food is Medicine Intervention

MUTTON-HF（醫療化應用定制傳統食物以優化心力衰竭營養）：一項本土食物即藥物的干預措施隨機對照試驗

匯報人：Lauren A. Eberly

FCR V

北京時間：3月30日 6:00-7:00

Two-Year Outcomes of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation: The TRISCEND II Randomized Trial

經導管三尖瓣置換治療重度三尖瓣反流的兩年結果：TRISCEND II 隨機試驗

匯報人：Vinod H. Thourani

Efficacy and Safety of BHB/HRS-1893 in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study

BHB/HRS-1893在有癥狀的梗阻性肥厚型心肌病中的療效與安全性：一項為期12周的2期研究結果

匯報人：康連鳴 中國醫學科學院阜外醫院

The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-inferiority Randomized Trial

心房起搏支持在心臟再同步化治療中的作用：一項非劣效性隨機試驗

匯報人：Mauro Biffi

Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI

行直接經皮冠狀動脈介入治療的STEMI患者的院前肝素給藥

匯報人：Misa Fister